Skip to main content
Premium Trial:

Request an Annual Quote

Pronto Diagnostics to Distribute Vermillion's OVA Test in Israel, Palestinian Territories

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today announced a definitive agreement with Pronto Diagnostics to serve as the exclusive distributor of the OVA1 ovarian cancer test in Israel and the Palestinian territories.

Pronto will begin offering the test to the private payor market and begin the regulatory process to make the test available to the publicly funded Israeli HMO market.

Financial and other terms of the agreement were not released.

In a statement, Gail Page, president and CEO of Vermillion, said that Israel and the Palestinian territories represent a market opportunity of about 6 million women, and the deal with Pronto "further supports our expansion efforts as we continue to develop our international strategy in concert with the efforts already underway in the US."

Based in Israel, Pronto offers a clinical laboratory, regulatory expertise, a broad distribution network, and experience distributing oncology products in its geography, Vermillion said.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.